Items tagged with Scientific research
TB bacteria evolve at alarming rate (post)
Researchers from the Vavilov Institute of General Genetics of the Russian Academy of Sciences (VIGG) and the Moscow Institute of Physics and Technology (MIPT) have established a catalog of mutations in 319 virulence genes of mycobacteria that cause tuberculosis. These genes encode proteins that suppress human immune response. Further analysis identified a set of three mutations which may enable mycobacteria to develop rapidly in an immunocompromised environment. The emerging strains of TB pathogens require new treatment approaches including the development of new genetically engineered vaccines that take into account both the immune status of a patient and the specific virulence features of a pathogen. The article was published in Genome Biology and Evolution (Oxford University Press, UK).
Major research funders and international NGOs to implement WHO standards on reporting clinical trial results (post)
18 May 2017 | GENEVA - Some of the world’s largest funders of medical research and international non-governmental organizations today agreed on new standards that will require all clinical trials they fund or support to be registered and the results disclosed publicly.
Researchers develop protocol to analyze many cells at once (post)
Rutgers researchers have developed a new way to analyze hundreds of thousands of cells at once, which could lead to faster and more accurate diagnoses of illnesses, including tuberculosis and cancers.
Readily available antibiotic could help to curb lung damage from TB (post)
Imperial scientists have found how a common antibiotic could help reduce lung destruction in people with Tuberculosis (TB).
Blocking TB germs’ metabolic ‘escape pathways’ may be key to better, shorter treatment (post)
CORVALLIS, Ore., 30 May 2017 – New research suggests the bacteria that cause tuberculosis alter their metabolism to combat exposure to antimicrobials, and that these metabolic “escape pathways” might be neutralized by new drugs to shorten the troublesome duration of therapy.
Mycobacteria use protein to create diverse populations, avoid drugs (post)
Subgroups of tuberculosis (TB)-causing bacteria can persist even when antibiotics wipe out most of the overall population. The need to eliminate these persistent subpopulations is one reason why TB treatment regimens are so lengthy. Now, researchers have shown that a single protein allows mycobacteria to generate diverse populations that can avoid TB drugs. The protein may be a target for intervention; blocking it might result in less mycobacterial diversity and shorten TB treatment courses. The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Tuberculosis bacterium may undermine immune regulation to drive disease progression (post)
The bacterium that causes tuberculosis -- Mycobacterium tuberculosis (Mtb) -- may disrupt human immune system regulation processes to promote destruction of lung tissue, according to new research published in PLOS Pathogens.
Organic compound found in red wine boosts the body's ability to fight drug-resistant TB (post)
An organic compound found in grape skins can stimulate the mouse immune system to fight even the most persistent tuberculosis strains. Such immune-based therapies, commonly used to treat cancer, could be the only hope against the spread of drug-resistant tuberculosis, says Amit Singhal, who led the study at the A*STAR Singapore Immunology Network.
Incentivizing antibiotic drug development to address antimicrobial resistance (post)
Experts agree that there is a need for a steady stream of innovation to address the constantly increasing rate of antimicrobial resistance. In a session entitled, “Bridging the ‘Valley of Death,’” the speakers described the gaps in antimicrobial development and discussed how government and private industry are working to address these gaps in antimicrobial drug development.
Regulators in EU, Japan and US take steps to facilitate development of new antibiotics (post)
The European Medicines Agency (EMA), the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) and the United States’ Food and Drug Administration (FDA) have agreed to align their data requirements for certain aspects of the clinical development of new antibiotics in order to stimulate the development of new treatments to fight antimicrobial resistance and protect global public health.
Page 24 of 74 · Total posts: 0
←First 23 24 25 Last→